Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that primarily affects the joints and may cause progressive joint damage and disability. As per Joshua J. Skydel et al. (2024), RA is the most common type of autoimmune arthritis, affecting up to 1% of the global population. This autoimmune disease burden underlines the importance of effective treatment and ongoing epidemiological assessment.
Base Year
Historical Period
Forecast Period

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Expert Market Research's “Rheumatoid Arthritis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of rheumatoid arthritis. It projects the future incidence and prevalence rates of rheumatoid arthritis cases across various populations. The study covers age, gender, and type as major determinants of the rheumatoid arthritis population. The report highlights patterns in the prevalence of rheumatoid arthritis over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of rheumatoid arthritis in the 8 major markets.
Regions Covered
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease in which the immune system mistakenly attacks the synovial lining of joints, causing inflammation, pain, swelling, and progressive joint damage. It develops through interactions among genetic susceptibility, environmental exposures, and immune dysregulation. Although it primarily affects the joints, it can also involve organs such as the lungs, heart, and eyes. Clinical patterns include seropositive rheumatoid arthritis, characterized by detectable rheumatoid factor or anti-citrullinated protein antibodies, and seronegative disease, in which these antibodies are absent despite compatible clinical findings.
|
Parameter |
Insight |
|
Largest Patient Pool |
India |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Women, older adults, individuals with a family history of rheumatoid arthritis, and people who smoke. |
|
Key Diagnostic Method |
Clinical examination, rheumatoid factor testing, anti-cyclic citrullinated peptide antibody testing, inflammatory markers, and imaging. |
|
Major Risk Factor |
Genetic susceptibility, cigarette smoking, female sex, increasing age, and environmental exposures. |
|
Major gap in the market |
Delayed diagnosis, limited access to specialist care, and affordability barriers to long-term treatment, particularly biologic therapies. |
The rheumatoid arthritis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the rheumatoid arthritis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for rheumatoid arthritis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Joshua J. Skydel et al. (2024), rheumatoid arthritis affects up to 1% of the global population. Healthline Media UK Ltd. also reports an estimated 1.3 million affected individuals in the United States, representing approximately 0.6%-1% of its population. |
|
Gender-Specific Cases of the Disease |
According to the World Health Organization (WHO), approximately 70% of people living with rheumatoid arthritis are women. This indicates a substantial gender difference in the disease burden, with women representing the majority of affected individuals. |
|
Age-Specific Cases of the Disease |
As per the World Health Organization, approximately 55% of people living with rheumatoid arthritis are older than 55 years. The disease burden therefore includes a considerable proportion of older adults, making age distribution an important epidemiological consideration. |
|
Ethnicity-Wise Cases of the Disease |
Epidemiological patterns may vary across populations because of differences in population characteristics, environmental exposures, and healthcare access. The supplied data does not establish rheumatoid arthritis-specific prevalence percentages for individual ethnic groups. |
|
Mortality and Survival Analysis of the Disease |
Rheumatoid arthritis contributes to long-term disease burden and may affect quality of life and socioeconomic outcomes. According to Chandrashekara et al. (2024), the disease has substantial individual and healthcare-system implications in India. The supplied data does not quantify rheumatoid arthritis-specific mortality or survival rates. |
|
Disease Type |
Prevalence |
|
Seropositive rheumatoid arthritis |
Seropositive rheumatoid arthritis is characterized by positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies. The supplied information indicates that it accounts for the majority of rheumatoid arthritis cases but does not provide a verified percentage. |
|
Seronegative rheumatoid arthritis |
Seronegative rheumatoid arthritis involves rheumatoid arthritis symptoms despite negative rheumatoid factor and anti-cyclic citrullinated peptide antibody tests. The supplied information does not establish a precise prevalence percentage for this subtype. |
|
Palindromic rheumatism |
Palindromic rheumatism is a rare, episodic condition involving intermittent inflammatory attacks. The supplied information suggests that approximately 10% of classic rheumatoid arthritis cases begin with palindromic-style episodes. |

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rheumatoid arthritis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to Healthline Media UK Ltd., approximately 1.3 million people in the United States have rheumatoid arthritis, representing an estimated 0.6%-1% of the population. This provides a country-specific indication of the disease burden. |
|
Germany |
As per the European Medicines Agency (EMA), rheumatoid arthritis prevalence in Germany is estimated at 0.8%, corresponding to approximately 560,000 patients among 69.4 million inhabitants. Around 25% of these patients receive advanced disease-modifying antirheumatic drug treatments. |
|
France |
According to Cécile Gaujoux-Viala et al. (2023), rheumatoid arthritis affects approximately 200,000 patients in France. This estimate indicates a substantial diagnosed patient population and provides a reference point for assessing national disease burden. |
|
Italy |
The rheumatoid arthritis burden in Italy is influenced by an aging population, the higher occurrence of the disease among women, and environmental risk factors such as smoking. Improved diagnostic practices and greater use of specialized rheumatology services may also increase the identification of cases. |
|
Spain |
The burden of in Spain is shaped by population aging, gender-related differences in susceptibility, smoking exposure, and excess body weight. Access to early arthritis clinics and improved recognition of symptoms can support earlier diagnosis and increase the number of identified cases. |
|
United Kingdom |
Rheumatoid arthritis prevalence in the United Kingdom is influenced by an aging population, female predominance, genetic susceptibility, and environmental exposures, particularly smoking. Differences in awareness, early referral, and access to rheumatology assessment may also affect diagnosis rates and the number of recognized cases. |
|
Japan |
According to Toshihiro Matsui et al. (2025), a national rheumatoid arthritis cohort included 26,607 patients, with a mean age of 64.16 years; 78.87% were women. These figures describe the study cohort rather than national population prevalence. |
|
India |
According to Chandrashekara et al. (2024), rheumatoid arthritis has an estimated prevalence of 0.75% in India, affecting approximately 5-7 million individuals. The disease also imposes substantial socioeconomic and healthcare burdens. |
Rheumatoid arthritis management across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India presents opportunities to improve early diagnosis, treatment access, and long-term disease control. In India, rising disease burden and substantial regional variation highlight the need for stronger awareness, timely referral, and access to rheumatology services. Across these markets, biologic disease-modifying antirheumatic drugs offer treatment options for patients with inadequate responses to conventional therapies. Opportunities include improving treatment affordability, optimizing patient selection, and supporting sustained disease monitoring.
Rheumatoid arthritis treatment aims to control inflammation, prevent irreversible joint damage, maintain physical function, and achieve sustained remission or low disease activity. Disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, are commonly used as initial therapy. Biologic DMARDs, including tumor necrosis factor inhibitors, interleukin-6 inhibitors, and other targeted agents, may be prescribed when conventional treatment is insufficient. Targeted synthetic DMARDs, such as Janus kinase inhibitors, provide additional options for selected patients. Nonsteroidal anti-inflammatory drugs and corticosteroids may help manage symptoms or short-term flares, while treat-to-target therapy supports regular disease assessment and treatment adjustment.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.